Medical news
-
Generating evidence to support clinical management and ensure access
We have entered an era of unprecedented growth in treatment options for hemophilia. A number of new treatments have, or will soon, enter the market,...
-
Access barrier to groundbreaking hepatitis C treatments
New medications unveiled in the last two years have revolutionized the treatment of hepatitis C (HCV) drastically improving patients’ chances of a cure. The challenge...
-
Providing guidance on product selection
There are several new treatment products for bleeding disorders available today and over the next couple of years, even more will likely become available to...
-
World Federation of Hemophilia product selection statement
The selection of safe, effective medicinal products is the responsibility of national regulatory and health agencies. In the case of clotting factor concentrates, whether plasma-derived...
-
WFH statement on end-product testing
End-product testing cannot be used to assure viral safety of clotting factor concentrates. The testing used for screening plasma for viral agents, whether performed on...
-
Zika virus
The World Health Organization (WHO) has declared the Zika virus a public health emergency of international concern. They define this as “an extraordinary event which is...
-
Data collection on a global scale
Collecting data from patients with hemophilia is important not only for advocacy purposes, but also to answer important questions about how hemophilia is managed in...
-
Electronic patient records and databases
Electronic patient records (EPRs) and databases are not new concepts for people with hemophilia. Generally, electronic patient records are developed as soon as patients are...
-
First recombinant von Willebrand Factor approved by FDA
The United States Food and Drug Administration (FDA) has approved Vonvendi, a recombinant von Willebrand Factor manufactured by Baxalta. The product is approved for on-demand...
-
Historical perspective on the treatment of hemophilia: Understanding the value of experience
As we enter into an era of increased scrutiny over healthcare costs and the associated benefits of providing certain treatment regimens, it has become quite...
